Tokyo, Japan and Cambridge, UK, 8August 2025 - Nxera Pharma ('the Company” or 'Nxera”; TSE: 4565) provides an update on ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare ...

Now, new clinical trial results suggest that an oral form of this medication may be coming soon—and the results so far are ...

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.